Trader consensus around a 94.5% implied probability of no hantavirus vaccine approval or availability by the end of 2026 reflects the early developmental stage of candidates, with most remaining in preclinical or Phase 1 testing as of mid-2026. Authoritative sources show no FDA, EMA, or equivalent approvals for New World strains like Andes virus, despite promising animal data such as single-dose mRNA constructs achieving full protection in Syrian hamster models. Inactivated vaccines exist only in limited Asian markets for Old World strains. Key barriers include the absence of Phase 3 efficacy trials, challenges in recruiting for rare-disease studies, and typical multi-year timelines from optimization to regulatory review. Accelerated funding could advance timelines, though realistic near-term shifts hinge on rapid human trial initiation and surrogate endpoint validation.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% chance
$131,279 Vol.
$131,279 Vol.
Dec 30, 2026
6% chance
$131,279 Vol.
$131,279 Vol.
Dec 30, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus around a 94.5% implied probability of no hantavirus vaccine approval or availability by the end of 2026 reflects the early developmental stage of candidates, with most remaining in preclinical or Phase 1 testing as of mid-2026. Authoritative sources show no FDA, EMA, or equivalent approvals for New World strains like Andes virus, despite promising animal data such as single-dose mRNA constructs achieving full protection in Syrian hamster models. Inactivated vaccines exist only in limited Asian markets for Old World strains. Key barriers include the absence of Phase 3 efficacy trials, challenges in recruiting for rare-disease studies, and typical multi-year timelines from optimization to regulatory review. Accelerated funding could advance timelines, though realistic near-term shifts hinge on rapid human trial initiation and surrogate endpoint validation.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Market Opened: May 4, 2026, 10:39 AM ET
Volume
$131,279End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus around a 94.5% implied probability of no hantavirus vaccine approval or availability by the end of 2026 reflects the early developmental stage of candidates, with most remaining in preclinical or Phase 1 testing as of mid-2026. Authoritative sources show no FDA, EMA, or equivalent approvals for New World strains like Andes virus, despite promising animal data such as single-dose mRNA constructs achieving full protection in Syrian hamster models. Inactivated vaccines exist only in limited Asian markets for Old World strains. Key barriers include the absence of Phase 3 efficacy trials, challenges in recruiting for rare-disease studies, and typical multi-year timelines from optimization to regulatory review. Accelerated funding could advance timelines, though realistic near-term shifts hinge on rapid human trial initiation and surrogate endpoint validation.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$131,279End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Trader consensus around a 94.5% implied probability of no hantavirus vaccine approval or availability by the end of 2026 reflects the early developmental stage of candidates, with most remaining in preclinical or Phase 1 testing as of mid-2026. Authoritative sources show no FDA, EMA, or equivalent approvals for New World strains like Andes virus, despite promising animal data such as single-dose mRNA constructs achieving full protection in Syrian hamster models. Inactivated vaccines exist only in limited Asian markets for Old World strains. Key barriers include the absence of Phase 3 efficacy trials, challenges in recruiting for rare-disease studies, and typical multi-year timelines from optimization to regulatory review. Accelerated funding could advance timelines, though realistic near-term shifts hinge on rapid human trial initiation and surrogate endpoint validation.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions